ArticlePharmaceutics2019
Montelukast Nanocrystals for Transdermal Delivery with Improved Chemical Stability.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Repurposing Non-oncologic Drugs via Targeted Nanocarriers for Cancer Therapy: Mechanisms, Synergistic Combinations, and Clinical Translation.AAPS PharmSciTech · 2026Review
- Stem Cell-Derived Exosomes Improve Neurological Dysfunction in a Rat Model of Moderate-to-Severe Cerebral Palsy.Stem cell reviews and reports · 2026Article
- Impacts of the Herbal Antimicrobial Compounds on the Antimicrobial Potency of Green Synthesized Copper Nanoparticles.Applied biochemistry and biotechnology · 2026Article
- Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Advances in Intranasal Delivery of Exosomes for Central Nervous System Disorders.Molecular neurobiology · 2025Review
- Advanced drug delivery systems for the management of local conditions.Therapeutic delivery · 2025Review
- Review
- Key processes in tumor metastasis and therapeutic strategies with nanocarriers: a review.Molecular biology reports · 2024Review
- Design of High-Payload Ascorbyl Palmitate Nanosuspensions for Enhanced Skin Delivery.Pharmaceutics · 2024Article
- Fabricating transdermal film formulations of montelukast sodium with improved chemical stability and extended drug release.Heliyon · 2023Article
- Novel Hydrogels for Topical Applications: An Updated Comprehensive Review Based on Source.Gels (Basel, Switzerland) · 2022Review
- Fabrication of pure-drug microneedles for delivery of montelukast sodium.Drug delivery and translational research · 2022Article
- Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery.International journal of nanomedicine · 2022Article
- High-Payload Nanosuspension ofInternational journal of nanomedicine · 2021Article
- Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine.Archives of toxicology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
A novel nanocrystal system of montelukast (MTK) was designed to improve the transdermal delivery, while ensuring chemical stability of the labile compound. MTK nanocrystal suspension was fabricated using acid-base neutralization and ultra-sonication technique and was characterized as follows: approximately 100 nm in size, globular shape, and amorphous state. The embedding of MTK nanocrystals into xanthan gum-based hydrogel caused little changes in the size, shape, and crystalline state of the nanocrystal. The in vitro drug release profile from the nanocrystal hydrogel was comparable to that of the conventional hydrogel because of the rapid dissolution pattern of the drug nanocrystals. The drug degradation under visible exposure (400-800 nm, 600,000 lux·h) was markedly reduced in case of nanocrystal hydrogel, yielding only 30% and 50% amount of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.